BeyondSpring Inc.

Equities

BYSI

KYG108301006

Biotechnology & Medical Research

Real-time Estimate Cboe BZX 01:02:49 2024-03-28 pm EDT 5-day change 1st Jan Change
3.555 USD -2.07% Intraday chart for BeyondSpring Inc. +20.30% +298.33%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
BeyondSpring Says First Patient Dosed in Phase 2 Trial of Lung Cancer Combination Treatment MT
Beyondspring Announces First Patient Dosed with Pembrolizumab, Plinabulin Plus Etoposide/Platinum in A Phase 2 Investigator-Initiated Study of First-Line Extensive-Stage Small-Cell Lung Cancer CI
BeyondSpring Inc. Announces Executive Changes CI
Top Premarket Decliners MT
BeyondSpring Inc. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
BeyondSpring Receives Non-Compliance Notice From Nasdaq MT
BeyondSpring Receives Notification From Nasdaq for Breaching Minimum Bid Price Requirements MT
Transcript : BeyondSpring Inc. - Special Call
BeyondSpring Inc. Announces New Data That Translates Preclinical Proof-Of-Concept to Clinical Evidence of Plinabulin?s Immunomodulating Activity CI
BeyondSpring Inc. Announces Retirement of Yanbin Xie as Board of Director CI
North American Morning Briefing : Traders Bet Data -2- DJ
North American Morning Briefing : China Data -2- DJ
North American Morning Briefing : Chip Stocks Take -2- DJ
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell Microcap Value Index CI
BeyondSpring Inc.(NasdaqCM:BYSI) added to Russell 3000E Value Index CI
North American Morning Briefing: Investors Eye Powell Testimony DJ
North American Morning Briefing : Focus Fixes on Fed, Powell DJ
BeyondSpring Inc. Announces New Data from Phase 1 Investigator Initiated Study Plinabulin’s Ability to Reduce Infectious Neutropenic Fever for Multiple Myeloma Patients Undergoing AHCT CI
North American Morning Briefing : China Trade Data -2- DJ
North American Morning Briefing : Stock Futures -2- DJ
North American Morning Briefing : Debt-Ceiling -2- DJ
Baird Adjusts Price Target on BeyondSpring to $1.25 From $4, Maintains Outperform Rating MT
BeyondSpring Inc. Reports Earnings Results for the Full Year Ended December 31, 2022 CI
BeyondSpring Inc. Auditor Raises 'Going Concern' Doubt CI
BeyondSpring Inc. Enrolls First Patient in Phase 2 Study with Plinabulin, Keytruda and Docetaxel in Patients with Metastatic Non-Small Cell Lung Cancer Who Progressed After Immunotherapy CI
Chart BeyondSpring Inc.
More charts
BeyondSpring Inc. is a clinical-stage global biopharmaceutical company. The Company is focused on using its technology platform for drug discovery and the development of therapies to improve clinical outcomes for patients with high unmet medical needs. The Company operates through two segments: the Plinabulin pipeline and Targeted Protein Degradation (TPD) platform. Plinabulin is being developed as a pipeline in a drug in various cancer indications as a direct anti-cancer agent and to prevent chemotherapy-induced neutropenia (CIN). Plinabulin is a small molecule derived from a natural compound found in marine microorganisms. It is a selective immunomodulating microtubule-binding agent (SIMBA), which may provide multiple therapeutic opportunities. The TPD platform is utilizing molecular glue technology to develop therapeutic agents and discover and develop new chemical entities for debilitating diseases and disorders. The Company is also developing three small-molecule immune agents.
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C
More Ratings